Status:
COMPLETED
Triple Therapy With Tegoprazan in H. Pylori Positive Patients_PILOT
Lead Sponsor:
HK inno.N Corporation
Conditions:
Helicobacter Pylori Infection
Eligibility:
All Genders
19-75 years
Phase:
PHASE3
Brief Summary
This study aims to compare safety and efficacy in an exploratory manner between a Tegoprazan triple therapy and a RAPAE01 triple therapy in H. pylori positive patients.
Detailed Description
A Randomized, Double-Blind, Active-controlled, Multicenter, Pilot Study to Investigate the Safety and Efficacy of a Tegoprazan triple therapy and a RAPAE01 triple therapy in H. pylori positive patient...
Eligibility Criteria
Inclusion
- H. pylori positive at screening
- Subjects who have upper gastrointestinal disease
Exclusion
- Having received prior therapy for eradication of H. pylori
- Prior use of P-CAB, proton pump inhibitors (PPIs), H2 receptor blockers within 14 days
- Prior use of H. pylori eradication effective antibiotics, bismuth within 28 days
Key Trial Info
Start Date :
January 21 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 29 2021
Estimated Enrollment :
102 Patients enrolled
Trial Details
Trial ID
NCT04128917
Start Date
January 21 2020
End Date
January 29 2021
Last Update
May 12 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chung-Ang University Hosptial
Seoul, South Korea